Table 1 Clinicopathological features of 16 pediatric High-Grade Glioma (pHGG) primary-recurrence tumor pairs analyzed in this study
From: Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas
Molecular Group | HGG case | Age/sex | Primary (P) Dx | Recurrence (R) Dx | Time to progression (months) | Interval between P and R (months) | Neuro-anatomical Location | Surgery#1 | Surgery#2 | Germline Available | Treatments between diagnosis and recurrence sample |
|---|---|---|---|---|---|---|---|---|---|---|---|
H3/IDH1 mutant | 1 | 14yo/M | GBM | GBM | 8.7 | 16.2 | Midline (Spine) | GTR | NA (autopsy) | Yes | RT+ TMZ, TMZ |
2 | 18yo/F | AA | GBM | 10.3 | 14.4 | Midline (Pons) | STR | NA (autopsy) | Yes | RT+ TMZ, TMZ, bevacizumab, vorinostat | |
3 | 13yo/F | GBM | GBM | 6.5 | 6.5 | Midline (Spine) | STR | NA (autopsy) | Yes | RT+ TMZ, rapamycin | |
4 | 4yo/F | GBM | GBM | 23.5 | 23.5 | Midline (Pons) | Biopsy | NA (autopsy) | No | RTÂ +Â vandatenib, dasatinib | |
5 | 12yo/M | GBM | GBM | 7.1 | 8.7 | Hemisphere | GTR | NA (autopsy) | No | RTÂ +Â TMZ, TMZÂ +Â bevacizumab | |
6 | 29yo/F | AA focal GBM | GBM | 45.2 | 45.2 | Hemisphere | STR | STR | No | RTÂ +Â TMZ, TMZ | |
7 | 19yo/F | AA | AA | 14.3 | 14.3 | Hemisphere | GTR | GTR | No | Surgery | |
H3/IDH1 wildtype | 8 | 15yo/F | AA | GBM | 12 | 13 | Midline (Thalamus) | Biopsy | NA (autopsy) | Yes | RT+ bevacizumab + TMZ, bevacizumab + TMZ + irinotecan |
9 | 18yo/M | GBM | GBM | 25.3 | 25.3 | Hemisphere | GTR | STR | Yes | RT, bevacizumab + irinotecan | |
10 | 10yo/F | HGG Gr III w neuronal component | HGG Gr IV w neuronal component | 9.3 | 17.3 | Hemisphere | GTR | STR | Yes | RT, lapatinib + bevacizumab, VP16 | |
11 | 14yo/F | GBM | GBM | 3.8 | 7.1 | Hemisphere | Biopsy | NA (autopsy) | Yes | RTÂ +Â TMZ, bevacizumab | |
12 | 17yo/M | GBM | GBM | 29.1 | 29.1 | Hemisphere | STR | STR | No | RT, VP16, BMT | |
13 | 19yo/M | AA | AA | 39.2 | 39.2 | Hemisphere | GTR | GTR | No | RT+ TMZ, TMZ | |
14 | 12yo/M | GBM | GBM | 13.8 | 13.8 | Hemisphere | GTR | GTR | No | RTÂ +Â TMZ, TMZÂ +Â lomustine | |
NF1 germline | 15 | 15yo/M | AA | GBM | 42.4 | 65.4 | Hemisphere | GTR | NA (autopsy) | Yes | RT, cisplatin + cyclophosphamide +topotecan + vincristine, TMZ, bevacizumab, rapamycin, cabozantinib |
16 | 23yo/F | LGG Gr II w pilocytic features | GBM | 9.5 | 9.5 | Hemisphere | GTR | STR | Yes | Surgery |